Skip to Main Content

Paper Details

Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>-Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL.
Cancer Discov
31
2021
B, B-ALL, B-cell cancers, B-cell malignancies, B-cell malignancy, B-cell receptor, CAR, CAR-T cells, CD19, CD72, In Vitro-Evolved Nanobody-Based CAR-T Cells, KMT2A, KMT2A/, KMT2A/MLL1-rearranged (MLLr) B, MLL1, MLL1-Rearranged B-ALL, MLLr B-ALL, Patients, SHIP1, chimeric antigen receptors, patients
Author NameAffiliation
Yu-Hsiu LinUniversity of California san francisco
Yu-Hsiu LinUniversity of California san francisco
Jeffrey D WhitmanUniversity of California san francisco
Sagar P BapatUniversity of California san francisco
Ansuman T SatpathyStanford University
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California san francisco
Aashish ManglikUniversity of California san francisco
Arun P WiitaUniversity of California san francisco
Arun P WiitaUniversity of California san francisco
  • 1 - 9

Datasets

Release 1.2